Author Archives: admin


Stem Cell Clinic > Articles by: admin

The Foundation of Hope and Innovation Partners with Venice Family Clinic to Provide Free Mammograms – GlobeNewswire

By Stem Cell Clinic

CERRITOS, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- The Foundation of Hope and Innovation, a charity supported by The Oncology Institute, Inc. (NASDAQ: TOI), announced a $40,000 donation to Venice Family Clinic to fund mammography services to women in Los Angeles. The donation will fund 10 free mammography days throughout greater Los Angeles.

The Foundation of Hope and Innovation selected Venice Family Clinic to be the first grant recipient of 2022 because of its 50-year history of providing primary care, specialty care, dental care, and mental health services to their community. Venice Family Clinics services align closely with The Foundation of Hope and Innovations founding principles: advance treatment options for patients and fill the gaps in healthcare delivery, including early detection of cancer and mental health support for patients.

Early detection of cancer is critically important to ensure prompt treatment and optimal outcomes, shared Dr. Daniel Virnich, Board President for The Foundation of Hope and Innovation. By partnering with a well-respected non-profit healthcare provider like Venice Family Clinic, we can ensure that more people have access to affordable cancer screening services and timely cancer treatment.

Venice Family Clinic provides high-quality, comprehensive health care to families and individuals who might otherwise go without the care they need. With 17 locations serving nearly 45,000 patients, Venice Family Clinic increases access to quality healthcare for Angelinos in need and helps ensure more people have access to early cancer screenings.

The generous donation by The Foundation of Hope and Innovation will ensure 200 patients access mammograms they may not have otherwise been able to access, added Rigoberto Garcia, Director of Health Education at Venice Family Clinic. We are thrilled to be able to extend these services to more patients.

About The Foundation of Hope and InnovationThe Foundation of Hope and Innovation believes that every patient, and their family, deserves access to high quality care and support services. They are committed to filling gaps in healthcare delivery, including early detection and mental health support. For more information visit http://www.foundationofhopeandinnovation.org.

About The Oncology Institute, Inc.Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 80+ employed clinicians and more than 600 teammates in 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit http://www.theoncologyinstitute.com.

Visit link:
The Foundation of Hope and Innovation Partners with Venice Family Clinic to Provide Free Mammograms - GlobeNewswire

The path to least resistance: How our researchers are outsmarting cancers survival skills – Cancer Research UK News

By Stem Cell Clinic

Breast cancer cells Credit: NCI

Drug resistance is one of biomedicines biggest threats, standing in the way of cures for all manner of viruses, infections and diseases, including cancer. But our scientists across the country are working hard to tackle it.

After a shock breast cancer diagnosis in January 2021 at the age of 48, doctor and mother Tina* underwent six months of chemotherapy, which for many people with early-diagnosed breast cancer can be curative. But a test following treatment confirmed the presence of residual cancer cells. Cells that had somehow survived the treatment onslaught. Cells that indicate the cancer could return. When I was told that my treatment hadnt been entirely successful, I initially felt very upset, Tina recalls. Id had a difficult time through chemo, needing multiple blood transfusions and experiencing multiple delays in treatment due to low blood counts. To then be told that there seemed to be residual disease due to chemo resistance was very hard to hear.

To be told after treatment that there seemed to be residual disease due to chemo resistance was very hard to hear Tina, breast cancer patient

Despite the huge progress weve made in breast cancer survival which has doubled in the UK over the past 40 years Tinas is a reality for many women with triple negative breast cancer, a subtype that can be harder to treat. For these women, when cancer does recur its more difficult to get on top of, explains Cancer Research UK clinician scientist Dr Sheeba Irshad. Dr Irshad is part of a growing cohort across our institutes and centres who are working to expose and exploit the mechanisms that allow some cancer cells to resist treatment (from chemotherapy to targeted treatments and even immunotherapies), lay dormant and then re-emerge later, when theyre harder to eradicate.

Drug resistance is a major reason why cancer regrows after treatment, so its also a significant contributor to people not surviving their disease, confirms Professor Dan Tennant, a Cancer Research UK biochemist at the University of Birmingham. Hes setting his sights on hypoxia a low-oxygen state in cells that occurs in most solid cancers and is a leading cause of drug resistance. Like all cells, cancer cells need oxygen to survive and multiply. When oxygen is scarce, theyre forced to adapt, finding compensatory ways to complete fundamental processes. Whats left is a cancer cell with a markedly different metabolism than a cancer cell with a normal oxygen supply. And one that stands out to someone like Professor Tennant, whos investigating how cancer cells survive such hostile conditions.

I dont think its a coincidence that, for example, glioblastoma an aggressive brain tumour is one of the most hypoxic tumour types and also incredibly resistant to treatments, he reasons. Given that hypoxic cells are some of the most drug-resistant cells within a tumour, by targeting them, we can directly alleviate resistance. And because the rest of the body has a normal oxygen supply, going after just the hypoxic cancer cells means patients should experience fewer negative side effects. Thinking about long-term therapy and a persons quality of life, thats a huge bonus, he adds.

Earlier this year, Professor Tennants team landed on a promising drug target. By feeding hypoxic cells nutrients such as sugars and watching how they use them compared to cancer cells with normal oxygen levels, they identified an enzyme that plays a critical role in hypoxic cells. When they removed the enzyme from cancer cells in mice, it caused the hypoxic tumour cells to die.

Despite this focus on the most fundamental elements of biology, Professor Tennant and his team are making steady progress toward the clinic not least because just 50 metres away, Cancer Research UK neurosurgeon Professor Colin Watts is collecting tissue samples from volunteer patients and passing them to the team so they can check their lab-based models against the real thing. The data generated on each side quickens the pace of progress. As Professor Tennant explains, Now, when we take our discovery science and try to translate it into new therapies, it has a better chance of working.

Its an attitude shared by Professor Stephen Tait at the Cancer Research UK Beatson Institute in Glasgow, whos also eager to use our vast clinical network to translate lab discoveries swiftly. He and his team are examining what happens when treatments do their job well but cause harmful unintended consequences. They found that when chemotherapy successfully kills a cancer cell, the dying cell can emit a protein that acts as a protector to neighbouring cancer cells, shrouding them from chemotherapy and allowing them to emerge unscathed. Professor Tait now hopes to test this by combining chemotherapy with a drug to inhibit this protein.

Its promising work, but perhaps more exciting is some of the teams earlier research, which is now flying towards the clinic thanks to an alliance set up by Cancer Research UK. Its based on their discovery that by blocking a class of proteins called caspases before a cancer cell is killed, the dying cell releases signals to the immune system. In normal circumstances, the immune system ignores cell death if it didnt, it would constantly be responding to the billions of cells that die within us each day. But with the immune system alerted, any leftover cancer cells can be ambushed and killed. Professor Tait is modest about the discovery: Like a lot of things in research, if you just stay alert, you see exciting stuff going on, he says. But their findings could lead to a new class of treatments that combine the strength of chemotherapy with the bodys perceptive immune response.

Back in Birmingham, Cancer Research UK cell biologist Dr Clare Davies is also making clinically relevant fundamental discoveries. Shes studying breast cancer stem cells, which initiate breast tumours. These cells are inherently chemo-resistant because they can repair the DNA damage that chemotherapy induces, she explains. They manage to do this because they have enhanced genes and mechanisms that control DNA repair pathways. These cells also multiply slower than other cancer cells, and because chemotherapy actively targets rapidly dividing cells, they face less bombardment.

We often think that science is a slow burn, but this shows it can really fly when people invest the time and money Dr Clare Davies

Developing drugs that specifically target the pathways enhanced in cancer stem cells would provide a new way to tackle chemo-resistant breast cancer. And Dr Davies and her team have identified an enzyme that they believe helps keep cancer stem cells alive by increasing these pathways. If we can inhibit this enzyme while also delivering chemotherapy, we can block the repair mechanisms and push the cancer stem cell over the edge, she explains, suggesting that we could cut cancer recurrence off at the source. Cancer is clever. It evolves, she says. We must understand the mechanisms underlying this evolution by studying cancer stem cells.

Dr Davies is now working with a pharmaceutical company to progress this work to patients through a clinical trial. We often think that science is a slow burn, but this shows it can really fly when people invest the time and money.

While these steps forward are cause for enthusiasm, they must also be met by innovation and resource in the clinic. Thats why Dr Irshad is leading a clinical trial platform named PHOENIX, which aims to accelerate the drug development pipeline for hard-to-treat breast cancers. Biopsies taken before and after treatment help the team understand the chemo-resistant disease in each individual patient and monitor the efficacy of specific drugs. These short-term efficacy trials allow us to design better trials with a higher likelihood of success, Dr Irshad explains.

Its then that the progress made in breast cancer survival really begins to count. Were lucky in breast cancer care that if secondary cancer is likely, we do have options for our patients, she adds. We can be proactive and that really matters.

With so many advances in drug discovery over the past few decades from improving chemotherapy and radiotherapy, to delivering targeted treatments and immunotherapies drug resistance deals a cruel blow. Only by bridging the biomedical and clinical worlds, and working in partnership with health systems and philanthropic partners, can we create the infrastructure and funding required to support our researchers and clinicians as they strive to remain one step ahead and ensure people like Tina arent left in limbo, waiting to be told whether their cancer has returned.

Researcher images from top to bottom: Dr Sheeba Irshad, Professor Dan Tennant, Professor Stephen Tait, Dr Clare Davies

I found out I had breast cancer on Wednesday 13 January, 2021. I remember the day well.

When I was told that my treatment hadnt been entirely successful, I initially felt very upset. Id had a difficult time through chemo, needing multiple blood transfusions and experiencing multiple delays in treatment due to low blood counts. To then be told that there seemed to be residual disease due to chemo resistance was very hard to hear.

From the outset, my hospital team have been fantastic. The oncologists always had a positive approach. As a mother of young children, I felt that this was essential. And when Dr Irshad told me that I would be entered into the trial, I felt hopeful and grateful that it was possible.

Its incredibly important that researchers like Dr Irshad continue vital research in this area. I never thought I would get breast cancer. I have become friends with a lot of women with breast cancer since my diagnosis. Were all so different. I would give anything to know what caused it. Im hoping that, with research, not only will we find treatments but also causes. I have a daughter and would not want her to go through what I have been through. Currently, Im doing really well. I have returned to work fully and lead a normal life. Lots of good things have happened as a result of my diagnosis. Ive realised how many people care for me and my family and I now lead a healthier lifestyle.

*Name has been changed at the request of the contributor.

Were tremendously grateful for funding weve received from supporters including Gonzalo and Maria Garca, Garfield Weston Foundation, Denise Leffman Trust and Mike Jackson, which has helped facilitate the work featured in this article.

Continued here:
The path to least resistance: How our researchers are outsmarting cancers survival skills - Cancer Research UK News

Stem Cell Concentration System Market Research Report Contains Key Players, Industry Overview, Supply Chain, Analysis And Forecast To 2021- 2026 The…

By Stem Cell Clinic

New York, United States: The global Stem Cell Concentration System Market research is an intelligence report with meticulous efforts undertaken to check the proper and valuable information by Decisive Markets insights. The info which has been looked upon is completed considering both, the prevailing top players and therefore the upcoming competitors. Business strategies of the key players and therefore the new entering market industries are studied very well. Well explained SWOT analysis, revenue share and call information are shared during this report analysis. It also provides market information in terms of development and its capacities.

Kindly click on the link below if you intend to make a direct purchase @:-https://www.decisivemarketsinsights.com/stem-cell-concentration-system-market/52519406/buy-now

Various factors are accountable for the markets growth trajectory, which are studied at length within the report. additionally, the Stem Cell Concentration System Market report lists down the restraints that are posing threat to the worldwide market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and products substitute, and therefore the degree of competition prevailing within the market. The influence of the most recent government guidelines is additionally analyzed thoroughly within the report. It studies the world markets trajectory between forecast periods.

Quicky avail limited copies of the Sample of the Stem Cell Concentration System Market report: visit @ https://www.decisivemarketsinsights.com/stem-cell-concentration-system-market/52519406/request-sample

Stem Cell Concentration System Market Segmentation- By Type : Syringes Bone Marrow Collection Needles Anticoagulant and Concentrating Devices Others By Application : Hospital Clinic Diagnostic Laboratories Key Players : EmCyte Terumo Perkin Elmer Zimmer Biomet Teleflex Argos Technologies Avita Medical Arthrex

The global market research report offers:

It offers a descriptive analysis of demand-supply chaining within the global market. Market definition of the worldwide market together with the analysis of various influencing factors like drivers, restraints, and opportunities. Extensive research on the competitive landscape of the world market. Identification and analysis of micro and macro factors that are and can affect the markets growth. A comprehensive list of key market players operating within the global market. Analysis of the various market segments like type, size, applications, and end-users. Figures, charts, graphs, pictures to explain the market clearly. Statistical analysis of some significant economics facts.

The cost analysis of the worldwide market has been performed while keeping in sight manufacturing expenses, labour cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors like Supply chain, downstream buyers, and sourcing strategy are assessed to supply an entire and in-depth view of the market. Buyers of the report will be exposed to a study on market positioning with factors like target client, brand strategy, and price strategy taken into consideration.

Request for discount if you intend to purchase the report immediately: https://www.decisivemarketsinsights.com/stem-cell-concentration-system-market/52519406/request-discount

Key questions answered within the report include:

What are the key outcomes of Porters five forces analysis and therefore the SWOT analysis of the key players functioning within the global market? This report gives all the knowledge regarding industry overview, analysis and revenue of this market. What are the market opportunities and threats faced by the vendors within the global market? What will be the market size and therefore the rate of growth by the tip of the forecast period? What are the key global market trends impacting the expansion of the market? What are the potential growth opportunities and threats faced by the leading competitors within the market?

In order to make a pre- order inquiry kindly click on the link below: https://www.decisivemarketsinsights.com/stem-cell-concentration-system-market/52519406/pre-order-enquiry

Kindly contact us and our expert will get back to you within 30 minutes:

Decisive Markets Insights Sunil Kumar Sales Head Email [emailprotected] Website-https://www.decisivemarketsinsights.com/ US +18317045538 UK +441256636046 Address:- 26, Broadway, Suite 934, New York , 10004

Social Links: Twitter-https://twitter.com/decisivemarket

Linkedin-https://www.linkedin.com/company/decisive-markets-insights

Go here to read the rest:
Stem Cell Concentration System Market Research Report Contains Key Players, Industry Overview, Supply Chain, Analysis And Forecast To 2021- 2026 The...

NEW HEMATOLOGY CHIEF AND DIRECTOR OF THE WESLEY CENTER FOR IMMUNOTHERAPY NAMED FOR UNIVERSITY HOSPITALS SEIDMAN CANCER CENTER – 69News WFMZ-TV

By Stem Cell Medical Center

CLEVELAND, May 25, 2022 /PRNewswire/ -- One of America's top cancer doctors with a national and international reputation for cancer research will lead the new Wesley Center for Immunotherapy at University Hospitals Seidman Cancer Center as well as the Division of Hematology.

Koen van Besien, MD, PhD, comes to UH Seidman Cancer Center from New York-Presbyterian Hospital, where he has been Director of the Stem Cell Transplant Program and an attending physician. He is also a Professor of Medicine at Weill Cornell Medical College in New York City.

Dr. van Besien will lead the Wesley Center for Immunotherapy at UH Seidman Cancer Center, a cellular therapy facility that generates CAR-T, NK cell and other cellular-based therapies. Physician-scientists engage in groundbreaking research and bring new, life-extending immunotherapy treatments to patients. UH experts are creating cells for treatment in just eight days - an innovation that allows UH Seidman Cancer Center physicians to deliver life-enhancing therapy more quickly than previously possible.

With an established reputation for clinical research and care, Dr. van Besien has made numerous contributions to the field of cellular therapy and stem cell transplantation. Most recently, he has focused on methods to extend the use of transplantation to more patients in need. His group has recently reported the first successful transplant for a patient with HIV and leukemia using a haplo-cord graft - a unique procedure developed by his team. The patient remains free of HIV and leukemia more than four years after transplant.

Dr. van Besien is Editor in Chief of the Journal of Leukemia and Lymphoma and a member of the editorial review boards of the journals Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. His NIH-supported research has been published in more than 300 peer-reviewed papers.

Dr. van Besien completed medical school and clinical training at College ND de la Paix in Namur and the University of Leuven, both in Belgium. He holds a PhD from the University of Maastricht in the Netherlands. He completed his hematology/oncology fellowship at Indiana University and in Bruges, Belgium. Dr. van Besien has served on the faculty of MD Anderson Cancer Center in Houston. He also directed transplant programs at the University of Illinois for four years and at the University of Chicago for a decade.

He is fluent in five languages: English, Dutch, German, Spanish and French.

Dr. van Besien joins UH Seidman Cancer Center on July 15.

About University Hospitals Seidman Cancer Center/Cleveland, Ohio

UH Seidman Cancer Center is the only freestanding cancer hospital in Northeast Ohio, where all clinicians and staff are dedicated to the prevention, diagnosis and treatment of cancer while researching new and innovative treatment options through clinical trials. Nationally ranked cancer care is also available to patients through the 11-county region at 16 community-based locations. Our UH Seidman specialists make up 14 cancer-specific teams focused on determining integrated care plans tailored to patient's needs. UH Seidman Cancer Center is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, one of 52 comprehensive cancer centers in the country. Patients have access to advanced treatment options, ranging from a pioneering stem cell transplant program founded more than 40 years ago and a wide range of immunotherapy to the first and only proton therapy center in northern Ohio for adults and children. Go to UHhospitals.org/Seidman for more information.

About University Hospitals / Cleveland, Ohio Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 23 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system's flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University and the Technion Israel Institute of Technology. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including "America's Best Hospitals" from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visit UHhospitals.org.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.

View original content:https://www.prnewswire.com/news-releases/new-hematology-chief-and-director-of-the-wesley-center-for-immunotherapy-named-for-university-hospitals-seidman-cancer-center-301555364.html

SOURCE University Hospitals Cleveland Medical Center

Original post:
NEW HEMATOLOGY CHIEF AND DIRECTOR OF THE WESLEY CENTER FOR IMMUNOTHERAPY NAMED FOR UNIVERSITY HOSPITALS SEIDMAN CANCER CENTER - 69News WFMZ-TV

UAE powerhouse VPS Healthcare launches Burjeel Holdings to scale the next generation of its growth – PR Newswire

By Stem Cell Medical Center

"Burjeel Holdings enables us to consolidate our healthcare offerings under one platform to create an integrated ecosystem, which will continue our vision to offer end-to-end health solutions under a single window. As we embark on our expansion journey, the platform will provide the foundation to scale up operations in new geographies in the GCC and beyond. It will also enable us to take strategic corporate actions needed to drive our future growth," said Dr. Shamsheer Vayalil, Chairman and Managing Director, VPS Healthcare. "We are proud to launch this exciting next phase of growth on the sidelines of the World Economic Forum Annual Meeting in Davos as a representation of our vision to explore, expand, and grow our capabilities."

Burjeel Holdings will operate nearly 60 assets catering to all socio-economic segments across a range of brands, including Burjeel Hospitals, Medeor Hospital, LLH Hospital, Lifecare Hospital, and Tajmeel. Its flagship facility, Burjeel Medical City, is the largest private hospital in the UAE and the only ESMO-accredited center. In addition to having renowned world-class centers of excellence, Burjeel Holdings consolidates the largest diagnostic network in the UAE and the largest comprehensive cancer center in the nation. Burjeel Holdings will be instrumental in continuing VPS Healthcare's mission of delivering quality and inclusive medical care to people around the world.

Connecting care, scale, and community to benefit refugees from Ukraine

Dr. Shamsheer began his entrepreneurial career with a vision to ensure healthcare equity. In his journey towards fulfilling this vision, he has also focused on outreach through humanitarian efforts. Alongside the launch of Burjeel Holdings, Dr. Shamsheer, a highly regarded philanthropist, announced a commitment of 50 pediatric stem cell transplantations to support Ukraine as well as additional support on behalf of those who join the pledge of support at Burjeel House in Davos.

Dr. Shamsheer and VPS Healthcare have been at the forefront of many humanitarian initiatives over the last 15 years. In 2018, VPS Healthcare enabled the treatment of Yemeni war victims at its hospitals in India. The organization offered the '100 Free Heart Surgeries' initiative for those in need as a tribute to the late H.H. Sheikh Zayed bin Sultan Al Nahyan.

"I am pleased to announce our commitment of support for those affected by the conflict in Ukraine. This contribution is being made toward the important task of rebuilding a strong community in the war-torn region. We have seen that children, especially those undergoing cancer treatment, are suffering the most in this very unfortunate conflict. Burjeel Holdings will look to provide them with the care they desperately need," said Dr. Shamsheer.

VPS Healthcare announced the launch of Burjeel Holdings and its commitment to supporting the Ukrainian refugees at the Burjeel House on the sidelines of the World Economic Forum Annual Meeting in Davos. The Burjeel House will convene intentional, collaborative dialogues on topics like catalyzing equitable health training, and advancing medical innovation.

Contact: M Unnikrishnan [emailprotected]

SOURCE Burjeel Holdings

Go here to see the original:
UAE powerhouse VPS Healthcare launches Burjeel Holdings to scale the next generation of its growth - PR Newswire

Cord Stem Cell Banking Market Trends Global Industry Analysis, Top Manufacturers, Growth, Opportunities & Forecast to 2028 The Daily Vale – The…

By Stem Cell Medical Center

Global Cord Stem Cell Banking Marketsurvey report has been generated with the systematic gathering and evaluation of market information for industry which is presented in a form that explains various facts and figures to the business. This market research report contains a thorough analysis of the market and numerous related factors that range from market drivers, market restraints, market segmentation, opportunities, challenges, and market revenues to competitive analysis. It lends a hand to companies to take decisive actions to deal with threats in niche markets. A brilliant team of analysts, experts, statisticians, forecasters and economists has worked rigorously to generate an advanced and all-inclusive research market report.A research report is a professional and in-depth market report that focuses on primary and secondary drivers, market share, possible sales volume, leading segments and geographical analysis of A industry. It shows that the rise in market value is generally attributed to the rising growth of the application industries and the subsequent rise in demand of applications. This market analysis report gives an examination of various segments that are relied upon to witness the quickest growth amid the approximate forecast frame. The competitive landscape section of the A global business report brings into light a clear insight about the market share analysis of major industry players.

Thecord stem cell banking marketis expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 22.2% in the above-mentioned forecast period. Increase in the number of parents storing their childs cord blood drives the cord stem cell banking market.

Get Sample Copy (Including Full TOC, List of Tables & Figures, and Chart) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=Global-Cord-Stem-Cell-Banking-Market

TOP KEY PLAYERS ofGlobal Clinical Trials MarketCord Stem Cell Banking Market

CBR Systems, Inc

Cordlife

Cells4Life Group LLP

Cryo-Cell International, Inc.

Cryo-Save AG

Lifecell

StemCyte India Therapeutics Pvt. Ltd

Viacord

SMART CELLS PLUS.

Cryoviva India

Global Cord Blood Corporation

National Cord Blood Program

Vita 34, ReeLabs Pvt. Ltd.

Regrow Biosciences Pvt. Ltd.

ACROBiosystems.

Americord Registry LLC.

New York Blood Center

Maze Cord Blood

GoodCell.

AABB

Stem Cell Cryobank

New England Cryogenic Center, Inc.

Market Scenario ofGlobal Clinical Trials MarketCord Stem Cell Banking Market

Cord stem cells banking is defined as the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Increased acceptance of stem cell therapeutics is the vital factor escalating the market growth, also rise in the new applications of stem cells indiseasetreatment, rise in the spending on the management of chronic diseases, rise in the growth in awareness about stem cell therapeutics and increase in the mergers and acquisitions by prominent players are the major factors among others driving the cord stem cell banking market. Moreover, rise in the technological advancements and modernization in the healthcare devices and risingresearch and developmentactivities in the healthcare sector will further create new opportunities for cord stem cell banking market in the forecasted period of 2021-2028.

However, high operating cost of stem cell therapeutics and lack of awareness in many developing economies are the major factors among others which will obstruct the market growth, and will further challenge the growth of cord stem cell banking market in the forecast period mentioned above.

The cord stem cell banking market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cord stem cell banking market contact Data Bridge Market Research for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Cord Stem Cell Banking MarketScope and Market Size

The cord stem cell banking market is segmented on the basis of storage type, product type, service type, source and indication. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis ofstorage type, the cord stem cell banking market is segmented into private banks, hybrid banks and public banks.

Based onproduct type, the cord stem cell banking market is segmented into cord blood, cord blood and cord tissue.

Based on service type, the cord stem cell banking market is segmented into collection & transportation, processing, analysis and storage.

Based on source, the cord stem cell banking market is segmented into umbilical cord blood, bone marrow, peripheral blood stem and menstrual blood

The cord stem cell banking market is also segmented on the basis of role of administration into cerebral palsy, thalassemia, leukemia, diabetes and autism.

This Report Answers the Following Questions:

What are the most significant market trends, challenges, and opportunities? How many segments will the market consist of? Which region is expected to dominate the market in terms of revenue? Which segment is likely to lead in terms of share in the coming years? What are the new strategies adopted by key players to strengthen their position?

Benefits of Purchasing of this Market Research Reports:

Customer Satisfaction:Our team of experts assists you with all your research needs and optimizes your reports. Analyst Support: Before or after purchasing the report, ask a professional analyst to address your questions. Assured Quality: Focuses on accuracy and quality of reports. Incomparable Skills: Analysts provide in-depth insights into reports.

To Gain More Insights into the Market Analysis, Browse Summary of the Research [emailprotected]https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

This Market Research Report Highlights:

Assessment of the market Premium Insights Competitive Landscape COVID Impact Analysis Historic Data, Estimates and Forecast Company Profiles Global and Regional Dynamics

Scope of Report:

Cord Stem Cell Banking Market survey report range from latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights to innovation. This report explains several market factors such as market estimates and forecasts, entry strategies, opportunity analysis, market positioning, competitive landscape, product positioning, market assessment and viability studies. Market drivers, market restraints, opportunities and challenges are also evaluated in this report under market overview which gives helpful insights to businesses for taking right moves. A market document is bestowed with full loyalty to provide the best service and recommendations.

A portion of the central issues canvassed in the report are: -Investigation of contenders -Whats Next -Market Data Forecast -Opportunity and Risks Assessment -Market Dynamics and Trends

Report Coverage- -It offers an all-encompassing business sector evaluation that remembers data for various market portions like innovation, arts, stage application, and others. -It incorporates an itemized investigation of the COVID-19 pandemics effect available. -It features different procedures taken on by significant market players to get development. -It features the most recent industry advancements. -It features market development surveyed by various topographical areas

Complete Report Details with Table of Content and [emailprotected]https://www.databridgemarketresearch.com/toc/?dbmr=Global-Cord-Stem-Cell-Banking-Market

Cord Stem Cell Banking MarketCountry Level Analysis

The cord stem cell banking market is analysed and market size insights and trends are provided by country, storage type, product type, service type, source and indication as referenced above.

The countries covered in the cord stem cell banking market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cord stem cell banking market due to rise in the presence of major market participants in the US, ongoing approval of stem cell lines for disease treatment, and increasing awareness among citizens in this region. Asia-Pacific is the expected region in terms of growth in cord stem cell banking market due to rise in the older population along with as surge in prevalence of chronic diseases, and rising per capita healthcare expenditure in this region.

The country section of the cord stem cell banking market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The cord stem cell banking market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for cord stem cell banking market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cord stem cell banking market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Cord Stem Cell Banking MarketShare Analysis

The cord stem cell banking market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to cord stem cell banking market.

Benefits of Purchasing this Market Research Reports:

Customer Satisfaction: Our team of experts assists you with all your research needs and optimizes your reports. Analyst Support: Before or after purchasing the report, ask a professional analyst to address your questions. Assured Quality:Focuses on accuracy and quality of reports. Incomparable Skills: Analysts provide in-depth insights into reports.

Global Cord Stem Cell Banking Marketbusiness report is a meticulous analysis of the existing scenario of the market, which covers several market dynamics. Competent data and brilliant forecasting techniques used in this market report are synonymous with accuracy and correctness. The report endows with the plentiful insights and business solutions that will support staying ahead of the competition. The most accurate way to forecast what the future holds is to understand the trend today and hence this report has been structured by chewing over numerous fragments of the present and upcoming market scenario. The world-class market research report is framed with the most excellent and sophisticated tools of collecting, recording, estimating, and analyzing market data..

The various aspects of A market survey report range from the latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights to innovation. This report explains several market factors such as market estimates and forecasts, entry strategies, opportunity analysis, market positioning, competitive landscape, product positioning, market assessment, and viability studies. Market drivers, market restraints, opportunities, and challenges are also evaluated in this report under market overview which gives helpful insights to businesses for taking right moves.

Key Highlights of Report: -Overview of key market forces propelling and restraining market growth -Offers a clear understanding of the competitive landscape and key product segments -An analysis of strategies of major competitors -Detailed analyses of industry trends -A well-defined technological growth map with an impact-analysis -Provides profiles of major competitors of the market. -Details of their operations, product and services. -Recent developments and key financial metrics.

Key Insights in the report: -Historical and current market size and projection up to 2029 -Market trends impacting the growth of the global taste modulators market -Analyze and forecast the taste modulators market on the basis of, application and type. -Trends of key regional and country-level markets for processes, derivative, and application -Company profiling of key players which includes business operations, product and services, geographic presence, recent developments and key financial analysis

Why Choose Data Bridge Market Research?

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others. We provide a variety of services such as market verified industry reports, technology trend analysis, Formative market research, strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

Top DBMR Healthcare Reports:

https://www.marketwatch.com/press-release/north-america-infrared-spectroscopy-market-analysis-by-applications-emerging-technologies-latest-innovation-top-trends-growing-demand-future-opportunities-till-2029-2022-05-23?mod=search_headline

https://www.marketwatch.com/press-release/europe-surgical-staplers-device-market-growth-at-a-rate-of-775-by-2029-industry-perspective-analysis-size-share-growth-segment-and-trends-2022-05-23?mod=search_headline

https://www.marketwatch.com/press-release/us-foot-and-ankle-allografts-market-is-expected-to-witness-market-growth-at-a-rate-of-412-in-the-forecast-period-of-2022-to-2029-conmed-corporation-wright-medical-group-nv-stryker-lattica-biologics-2022-05-23?mod=search_headline

https://www.marketwatch.com/press-release/us-ambulatory-x-ray-market-by-emerging-trends-business-strategies-developing-technologies-revenue-competitive-landscape-and-analysis-till-2029-2022-05-23?mod=search_headline

About Data Bridge Market Research, Private Ltd

Data Bridge Market ResearchPvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Contact Us

US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email [emailprotected]

Read the original post:
Cord Stem Cell Banking Market Trends Global Industry Analysis, Top Manufacturers, Growth, Opportunities & Forecast to 2028 The Daily Vale - The...

UW Fitness Day aims to strengthen community and bone marrow registry – University of Washington

By Stem Cell Medical Center

Administrative affairs | For UW employees | News releases | UW and the community

May 20, 2022

Participants at UW Fitness Day 2019 in Husky Stadium.University of Washington

The annual University of Washington Fitness Day returns as an in-person event on Monday, May 23. This years Fitness Day includes a fundraising and registration goal for Be The Match, the nations largest registry of bone marrow donors.

Fitness Day is a unique, campuswide workout to celebrate movement. The Seattle campus will host the event on the field at Husky Stadium, where participants will gather from 12:30 to 1:30 p.m. and complete a circuit workout with 20 stations led by expert coaches from UW Athletics and community partners. Workout stations will include strength training, cardio bursts, active recovery and yoga. All fitness levels are welcome and encouraged to participate. Participants will receive a free, performance tech T-shirt.

From 3:30 to 5 p.m., the festivities move to Red Square for Get in the Game, a joint effort with Be The Match intended to increase awareness of its marrow and stem-cell donor registry and encourage students to sign up for the registry. UW athletes will lead the peer-to-peer education effort with Football, Mens Basketball, Womens Basketball, Mens Soccer, Womens Soccer, Cheer and Dance, and Track teams participating.

Alexes Harris, UW professor of sociology, is leading the push to increase the registry at the event. Six years ago, Harris was diagnosed with a form of leukemia that required a bone marrow transplant but couldnt find a match on the registry.

Be The Match couldnt find me a match because people of color are underrepresented on the registry and ancestry matters when matching, said Harris, who added that she was fortunate to enter a clinicaltrial at Seattle Cancer Care Alliance and had a cord blood transplant that saved her life.I work with Be The Match in the name of people who did not find a match and were not able to live.

The goal is to raise $5,000 and sign up 500 new registry members. Participants are invited to make a $5 suggested donation when registering for UW Fitness Day.

After years of not being able to gather in person due to the pandemic, I am thrilled to see employees and students come together in community once again, said Mindy Kornberg, UW vice president for Human Resources. UW employees across campus and our medical centers work extraordinarily hard and this event is the epitome of centering employee well-being at work.

Fitness Day events are also being held Monday at Harborview Medical Center, UW Bothell and UW Tacoma. More information on all UW Fitness Day events at every location can be found on The Whole Us website.

For more information, contact Victor Balta at balta@uw.edu.

See more here:
UW Fitness Day aims to strengthen community and bone marrow registry - University of Washington

Hollings researcher studies how yogic breathing may reduce side effects of cancer treatment – Medical University of South Carolina

By Stem Cell Medical Center

"Breathe in from the nose and slowly exhale through the nose.

Class is in session inside the MUSC Wellness Centers auditorium as Sundar Balasubramanian, Ph.D., leads a yogic breathing class for participants in Survivors' Fit Club, a group for breast cancer survivors to find community and improve their overall fitness and well-being. Balasubramanian, a world-renowned expert in the field, is an MUSC Hollings Cancer Centerresearcher, cell biologist, certified yoga therapist and assistant professor in the Department of Radiation Oncology at MUSC.

He knows how important yogic breathing can be for overall health, especially for cancer patients and survivors. The Survivors' Fit Club session is just one of several programs and pilot studies that Balasubramanian is leading, seeking to quantify the benefits of this practice.

There are a lot of long-term chronic health issues that stem from cancer treatment, he said. We are looking for ways to improve aspects of survivorship that work in combination with the traditional standard of care. Breathing exercises can alter how we feel emotionally and how certain physiological changes are occurring. For example, breathing exercises can improve blood circulation, which can then help you keep a steady heart rate and create a sense of being energetic and relaxed.

Research is showing a wide range of potential benefits, including:

While there are a variety of yogic breathing exercises, the core purpose remains the same a slow, intentional inhale and exhale from the nose to center the participant and promote mindfulness. Balasubramanian also teaches participants how to incorporate an ocean sound from the throat as yet another breathing exercise.

One of his studies is looking at the impacts of yogic breathing in breast cancer patients. The 12-week study is open to breast cancer patients who have received radiation therapy within the last six months. It will continue recruiting patients through May 2023, Balasubramanian said.

Participants will receive a unique link to access an online yogic breathing app called Kumbi, which translates to to gather and hold, and complete three 10-minute-long exercises three times a day, five days a week. The telehealth aspect of the study allows breast cancer patients across the country who have recently undergone radiation therapy to join.

Everyone had to learn how to walk. Its something most of us do every day, he said. The same applies to breathing exercises. A lot of people say they know about breathing exercises, and some have even done a class on it. But how often are you doing it? Is it daily? How many times a day? Routine is important.

Balasubramanian said participants will complete questionnaires that will measure factors like stress levels, anxiety, sleep and quality of life. He hypothesizes that if you improve those factors, youll improve the overall health of the patient and improve the quality of her life.

Participants will be assigned to one of the two mindfulness groups. One will follow one traditional mindfulness exercise, and the other group will focus on yoga breathing exercises, he explained. Participants will engage with others taking part in the study and can also practice their mindfulness exercises on their own.

Balasubramanian isnt stopping with breast cancer patients. There are plans for him to work with the South Carolina Cancer Disparities Research Center (SC CADRE), a collaboration between MUSC Hollings Cancer Center and South Carolina State University, to develop newer yogic breathing tools (apps) for patients with breast, prostate and colorectal cancer who are receiving chemotherapy and radiation to study disparities in cancer outcomes.

Were very excited to have him on board, said Marvella Ford, Ph.D., co-director of SC CADRE.

She noted that Black people, whether with or without cancer, tend to have higher levels of inflammatory biomarkers than white people.

If you go into a cancer diagnosis already having these high levels of inflammatory biomarkers, it affects the treatment outcomes, she explained. Hes really making a connection between the act of yogic breathing and the levels of these biomarkers by showing that participating in a yogic breathing intervention substantially reduces the levels of these biomarkers and decreases bio-inflammation, which has been linked to improved cancer treatment outcomes.

Balasubramanian has also taken the yogic breathing exercises to the American Cancer Societys Hope Lodge in Charleston. The Hope Lodge, across the street from Hollings and the MUSC campus, provides free lodging for cancer patients who are in treatment but live more than 40 miles away from the hospital. There, Balasubramanian offers weekly 20-minute sessions to both patients and caregivers.

In a voluntary, anonymous survey of previous participants at the Hope Lodge, Balasubramanian found that nearly all participants reported the breathing exercises improved their stress levels. The yogic breathing also exceeded participants expectations in improving their appetites. Overall, 90% reported being very satisfied with the sessions, and 83% said they intended to continue the exercises at home.

In the study of breast cancer patients who have undergone radiation, participants will be asked to provide a total of eight saliva samples. In our research, weve found that people in a more relaxed state after yogic breathing produce more saliva, he said. Saliva isnt just digestive fluid. It also contains neurohormones, growth factors and proteins needed for our well-being.

Balasubramanian said research has shown that saliva contains tumor suppressors that could impact how cancer forms and grows. He also said that saliva can be examined for biomarkers that indicate stress.

Balasubramanian said these studies hit close to home, having grown up in India where yoga is a common practice. In 2015, he was asked to share his research and expertise on yogic breathing and overall health during a TEDxCharleston talk. Since then, hes been spreading awareness about the health benefits of yoga breathing.

Our goal is to use the findings from this study to expand it to all other cancer types at any stage, Balasubramanian said. Yoga breathing is something everyone can do, regardless of their physical abilities. We hope this provides our cancer patients and survivors another resource to lead a healthier life.

In the future, Balasubramanian said the goal is for the Kumbi app to be commercialized to expand its benefit for all patients.

For more information or to enroll in the breast cancer patients study, click here.

Here is the original post:
Hollings researcher studies how yogic breathing may reduce side effects of cancer treatment - Medical University of South Carolina

LUXA BIO Announces First Participant Dosed in Phase 1/2a Clinical Trial of Adult RPESC-RPE-4W for Dry Age-related Macular Degeneration – Business Wire

By Adult Stem Cells

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI), Rensselaer, New York, today announced transplantation of the cell product RPESC-RPE-4W into the first participant with dry age-related macular degeneration (dry AMD) in its Phase 1/2a clinical trial (NCT04627428) being conducted at the University of Michigan Kellogg Eye Center.

RPESC-RPE-4W is a cell product derived from the retinal pigment epithelium stem cell (RPESC) that is present in the adult human retina. This adult stem cell produces retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE). The cell product being used in the clinical trial is a progenitor stage RPESC-RPE cell obtained after 4 weeks of differentiation (RPESC-RPE-4W). The RPESC-RPE-4W progenitor stage cell has shown increased engraftment and vision rescue compared to more mature RPE cell products.

AMD with a loss of RPE cells results in loss of central visual acuity, leading to legal blindness in millions of patients, said Jeffrey Stern, MD, PhD, founder of NSCI. Our RPESC-RPE-4W cell transplantation trial aims to address the great unmet medical need presented by dry AMD, for which there is no approved therapy.

Laboratory studies of RPESC-derived RPE cells demonstrated they could perform the critical repertoire of cell functions carried out by normal RPE cells, including trophic factor release and phagocytosis. Sub-retinal implantation in an animal model of retinal degeneration showed that RPESC-RPE-4W cells engraft into the RPE layer. Transplanted RPESC-RPE-4W provided durable preservation of RPE cell functions and supported overlying photoreceptor cells, resulting in vision rescue that was maintained for the life of the animal. RPESC-RPE-4W has significant safety attributes in animal models, including lack of tumor formation.

Adult RPESC are obtained from eyes donated to eye banks. A single donor produces sufficient RPESC-RPE-4W cells for several hundred doses. The RPESC-RPE-4W cell product is being manufactured at the Cedars Sinai Biomanufacturing Center in Los Angeles and the formulated doses are shipped to the clinical site for implantation.

Dr. Rajesh Rao, the trial Principal Investigator at Kellogg Eye Center, transplanted 50,000 RPESC-RPE-4W cells under the macula of a study participant with advanced dry AMD. The Phase 1/2a study will enroll up to 18 participants to assess the safety, tolerability, feasibility, and preliminary efficacy of subretinal RPESC-RPE-4W in a dose escalation, open-label study. The trial is co-sponsored by the National Eye Institute of the National Institutes of Health under a Regenerative Medicine Innovation Project cooperative agreement.

About Luxa Biotechnology

Luxa Biotechnology (LuxaBio) is a clinical-stage biotechnology company developing a novel adult RPE stem cell therapy for dry AMD. The proprietary adult RPESC-RPE-4W stem cell product was developed at and licensed from the NSCI. LuxaBio is a partnership between the NSCI research institute and Y2 Solutions, a Korean company advancing RPESC in a clinical trial to test safety and efficacy as a potential therapy for dry AMD. LuxaBio maintains a robust research program at NSCI to develop the RPESC as an effective, commercially viable cell product. The Phase 1/2a Clinical Trial of RPESC-RPE-4W for the Treatment of Dry Age-related Macular Degeneration includes the Cedars Sinai Biomanufacturing Center, The Emmes Company, the University of Michigan Kellogg Eye Center and the National Eye Institute. For more information, please contact jeffreystern@luxabiotech.org.

Here is the original post:
LUXA BIO Announces First Participant Dosed in Phase 1/2a Clinical Trial of Adult RPESC-RPE-4W for Dry Age-related Macular Degeneration - Business Wire

Regenerative medicine: the quest to repair damaged hearts – British Heart Foundation

By Adult Stem Cells

From heart patches to gene therapy, Anna Clark explains the latest BHF-funded research in the cutting-edge field of regenerative medicine.

Regenerative medicine is at the frontier of research. Its a field of science that looks at different ways to repair (or regenerate) damaged areas of the body. This search is particularly urgent when it comes to the heart, which cant easily heal itself if it gets damaged.

One of the most common causes of damage is a heart attack, which happens when there is a blockage in an artery supplying the heart muscle, so the muscle cant get the oxygen it needs. When this happens, muscle cells can die and over time are replaced by scar tissue. This can mean the heart isnt pumping blood as well as it should: a condition called heart failure.

Heart failure can cause constant tiredness, as well as a build-up of fluid in the feet, legs and lungs. Around 920,00 people in the UK are living with heart failure, and although the symptoms can be treated, there is no cure. Heart failure contributes to thousands of deaths in the UK each year.

Sign up to our fortnightly Heart Matters newsletter to receive healthy recipes, new activity ideas, and expert tips for managing your health. Joining is free and takes two minutes.

Professor Sanjay Sinha and his team at the University of Cambridge are growing patches of real heart tissue in a dish. The result is a patch of heart tissue that contracts in a coordinated way, just like the heart does when it beats. The team aim to graft them onto damaged areas of the heart to repair it.

The process is not simple. They use stem cells special cells which can become any type of cell in the body. They are mainly found in embryos, but a small number of stem cells remain into adulthood, helping to replenish dying cells or repair damage. They can also be artificially created from adult cells, such as skin cells.

Professor Sinhas team use both embryonic and artificially created stem cells, giving them a specific mixture of proteins called growth factors to stimulate them into becoming heart muscle cells and epicardial cells (the cells which make the outer layer of the heart). They then put them on a scaffold made from collagen (the substance which holds bones, muscles, skin and tendons together) and incubate them for a couple of weeks. During this time, they must be cared for very carefully. The BHF-funded team hope that these patches will revolutionise the way we treat damage to the heart.

Scientists were funding are investigating ways to encourage the heart to grow new blood vessels, to help improve blood flow into areas that have become damaged.

In 1997, the exciting discovery was made that endothelial progenitor cells (a type of stem cell from the bone marrow) can be found in the blood of adults. These cells can turn into endothelial cells (the cells which line our blood vessels) so are thought to be involved in new blood vessel growth. Scientists are trying to better understand how they could be used to grow new blood vessels in the heart.

Dr Mairi Brittan and her team at the University of Edinburgh have discovered that endothelial progenitor cells might also be found in the adult blood vessel wall. They are now trying to understand more about them, what effects they have and how they could be controlled. In the future, this research could lead to clinical trials to test whether these special cells can repair damaged blood vessels.

In the later stages of pregnancy, more than a third of heart muscle cells in the unborn baby multiply to create new heart muscle. But this regenerative power declines within weeks of birth, and adult heart muscle cells rarely reproduce themselves.

Professor Mauro Giacca and his BHF-funded team at Kings College London are looking at how to stimulate heart muscle cells to multiply, just like they do in the unborn baby. The actions of the cells in your body, including whether they multiply, are controlled by your genes. We still need to learn more about which genes are switched on or off as the heart loses its ability to regenerate, so that we can try to restore this potential.

Professor Giacca and his team are testing nearly 20,000 siRNAs (short sequences of genetic material used to block the effects of specific genes). They will test each one to see how changing heart cells in that specific way affects their ability to multiply.

The team has already identified a sequence of genetic material which could be linked to stimulating regeneration. Professor Giacca hopes that in the future these findings could be used to help switch on the ability of heart muscle cells to multiply and repair the damaged heart, just like they can in the growing embryo. Regrowing hearts might seem like science fiction, but BHF-funded research means this may not be as far off as it first seems.

Published 23 May 2022

Go here to read the rest:
Regenerative medicine: the quest to repair damaged hearts - British Heart Foundation

→←